Cynosure Group’s Charles River Laboratories CRL Stock Holding History

Cynosure Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,477	Closed	-$494K	–	267
2025 Q4	$494K	Buy	+2,477	New	+$449K	0.05%	186

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cynosure Group's CRL Position: Q1 2026 in Review

Cynosure Group sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 2,477 shares — an estimated $494K sold.

Cynosure Group first reported a position in CRL in Q4 2025 and held it in 1 quarter. The position peaked at $494K in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Cynosure Group reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
Cynosure Group sold 2,477 Charles River Laboratories shares in Q1 2026, an estimated $494K.
Cynosure Group first reported a position in Charles River Laboratories in Q4 2025 and held it in 1 quarter.
Cynosure Group's Charles River Laboratories position peaked at $494K in Q4 2025.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.